| EntreMed Commences Phase 2 Study With MKC-1 In Pancreatic Cancer
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that it has commenced a multi-center Phase 2 clinical trial with MKC-1 in patients with advanced pancreatic cancer. The primary objectives of this study will be to determine the antitumor activity of orally-administered MKC-1 in unresectable or metastatic pancreatic cancer patients who have failed at least one prior chemotherapy regimen. The study will also assess the safety, tolerability and overall median survival time of pancreatic cancer patients treated with MKC-1. Massachusetts General Hospital Cancer Center is the lead institution for the study and Eunice Kwak, M.D., Ph.D., Assistant in Medicine, Tucker Gosnell Center for Gastrointestinal Cancers, will serve as the principal investigator.
DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM ...
ATLANTA, Oct. 17 /PRNewswire/ -- After completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that the pivotal Phase 3 clinical trial FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change. The trial is studying the use of Medidur FA for the treatment of diabetic macular edema (DME). FAME is a double masked, randomized, multi-center study that is following over 900 patients in the U.S., Canada, Europe and India for 36 months in support of a planned global registration filing, with safety and efficacy assessed after two years of follow-up. Last week, Alimera and pSivida announced that enrollment for the FAME study is complete. A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing studies.
Eugene Prince Coleman, 1937–2007
Eugene Prince Coleman died Oct. 26, surrounded by his family, after losing a battle against pancreatic cancer. It was one of the few fights that he lost in his long and memorable life in San Francisco. Born in Mississippi 70 years ago and raised in Cleveland, Coleman came to San Francisco in 1972 and, like many in that decade, found a home in the city. He never left and never, ever quit working to make it better. Coleman was one of the creators of modern, tolerant, progressive San Francisco. His decadelong service to South of Market as director of the Canon Kip Community House (until it was closed as the Episcopal Church turned away from the central city) was a model of dedicated, informed, and effective advocacy and service. He founded the first paratransit service for seniors in San Francisco.
New Marker To Identify Cancer Stem Cells Discovered
ScienceDaily (Dec. 12, 2007) Researchers at the University of Michigan Comprehensive Cancer Center have found a marker that can be used to identify stem cells in breast tumors, suggesting a potential simple test that could help determine the best treatment for breast cancer. .
Arius Announces New Findings In Cancer Antibody Programs
ARIUS Research presented new findings from its Trop-2 and CD59 antibody programs. ARIUS scientists will discuss the Company's Trop-2 and CD59 abstracts at the AACR press conference today at 9:30 a.m. PT."Both our Trop-2 and CD59 antibody programs have demonstrated novel approaches in treating cancer. Our Trop-2 antibody is a novel target and has been linked to aggressive cancers in the scientific literature, while our CD59 program has demonstrated the ability to foil a cancer cell's ability to evade the immune system," said Dr. David Young, President and CEO. "These programs, in addition to our CD44 cancer stem cell program, were generated through our proprietary drug discovery technology, FunctionFIRST(TM), which is inherently designed to produce novel antibodies and identify unique cancer targets."Trop-2 Proffered Paper PresentationARIUS' Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100 percent.
New Data Confirms That A Selective, Fully Human Anti-VEGF Antibody ...
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, reported that preclinical data presented at IBC's 5th Annual International Anti-Angiogenesis Conference showed that its anti-VEGF antibody R84 was as effective as Avastin(R) (bevacizumab) in inhibiting tumor growth in a mouse model of human breast cancer. R84 is a selective, fully human monoclonal antibody that blocks the cancer-promoting agent vascular endothelial growth factor (VEGF). R84 selectively blocks VEGF from binding only to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents may have potential advantages over non-selective approaches and Peregrine is now assessing R84 as a candidate for clinical development.
October 2006
I can find no reason why federal law is being waived for this except that many feel that Title IX, the gender equity law, applies only to how much money schools should be spending on school sports. In a Cape Cod Times editorial today they took the position that it was a good idea. Well, they didn't really stick out their neck; they said it is worth considering. My feeling is this: Schools should try single sex groupings it and see who it helps without tooting it all over the place as the answer. Results, in terms of test scores and emotional output should be studied. Doctoral dissertations should be encouraged to examine it and survey research should be funded to see how much, if at all, it helps. Finally, the question must be asked if it is worth setting aside Title IX and possibly the culture altering woman's movement to do it? We need to know these things before we get too infatuated with separating boys and girls at school.
Firefighters and cops can now sue city in state court
In a unanimous decision, the State Supreme Court has ruled in favor of an injured Seattle firefighter and the widow of a Seattle police officer, both of whom had sued the city for negligence. In an opinion published Thursday, the court justices found that both firefighter Kevin Locke and the widow of officer Gary Lindell had the right to sue the city under a provision of the state's pension plan for police and firefighters. "I'm overjoyed by it," Sgt. Rich O'Neill, president of the Seattle Police Officer's Guild, said of the ruling. "I think it sends a strong message to the city that officers and their families can hold the city liable." The ruling involves both the case of firefighter Kevin Locke and that of Margaret Lindell, widow of officer Gary Lindell.
|
